Avila Therapeutics, the Waltham, MA-based drug developer, is announcing today it will receive as much as $3.2 million from The Leukemia & Lymphoma Society to support development of a new therapy for B-cell related cancers. The drug, AVL-292, is designed to form a tight covalent bond to hit a target on immune system B-cells, called Bruton’s Tyrosine Kinase, or Btk. Avila plans to take the product candidate into its first clinical trial in 2010. Avila CEO Katrine Bosley told me more about this drug and Avila’s hepatitis C treatment, in a feature story last month.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
